A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
Conditions
Non-Hodgkin's Lymphoma
What is the purpose of this trial?
The purpose of this study is to evaluate response rate, survival, safety and tolerability of YM155 given in combination with rituximab in subjects with Non-Hodgkin's Lymphoma.
Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Both
Click here for detailed information about who can participate in this trial.
- Sponsor:
- Astellas Pharma Inc
- Dates:
- November 2009
- Last Updated:
- April 11, 2013
- Study HIC#:
- 1010007518
Clinicaltrials.gov ID: NCT01007292
For more information about this trial, contact:
Investigator
Francine Foss, MD
Principal Investigator
